Guidelines on Pericardial Diseases 2015 (TF18) - Task Force · PDF file- Cadila Pharma : Tuberculous pericarditis ... - Thermo Fischer Scientific : Cardiac markers ... - Eli Lilly

Adler Yehuda Nothing to be declared (2013-2014-2015)

Badano Luigi Paolo A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- SamsungMedison : Ultrasound (2013)

- Edwards Lifesciences : Clinical Event Comittee member (2013-2014)

- Sorin Group : Consultancy (2013-2014)

- GE Healthcare : Ultrasound (2013-2014-2015)

- Edwards Lifesciences : Heart valve prostheses. Clinical Event Comittee member (2015)

- Sorin Group : Heart valve prostheses. Consultancy (2015)

- Epygon : Start-up, bioprostheses. Advisory board (2015)

B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Epygon : Heart valve prostheses (2015)

D - Research funding (departmental or institutional).- GE Healthcare : Ultrasound (2013-2014-2015)

E - Research funding (personal).- GE Healthcare : Ultrasound (2013)

Baron Esquivias Gonzalo A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Bayer : Anticoagulation (2013-2014-2015)

- Boehringer-Ingelheim : Anticoagulation (2013-2014-2015)

- Daiichi Sankyo : Anticoagulation (2013-2014-2015)

- Pfizer : Anticoagulation (2013-2014-2015)

- Menarini : Ischemic disease (2015)

- Laboratorios Rovi : Ivabradine (2015)

D - Research funding (departmental or institutional).- Biotronik : Vasovagal syncope & Pacing (2013)

- Bayer : Anticoagulation (2015)

Bogaert Jan Nothing to be declared (2013-2014-2015)

27/08/2015

Guidelines on Pericardial Diseases 2015 (TF18) - Task Force

Expert Type of Relationship with Industry

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

1/33

Brucato Antonio A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Menarini : hyperuricemia (2013)

- Pharmintertrade sas : colchicine (2014)

D - Research funding (departmental or institutional).- FAR.G.IM S.r.L : colchicine (2014)

- ACARPIA : colchicine (2015)

Charron Philippe B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Servier : Heart failure and CAD (2013)

- Shire HGT : Lysosomal diseases (2013-2014-2015)

- Genzyme : Lysosomal diseases (2013-2014-2015)

D - Research funding (departmental or institutional).- Shire HGT : Fabry disease, Cardiomyopathies (2014)

Gueret Pascal A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Daiichi Sankyo, General Electric; Merck-Sharpe Dohme, Servier. : Myocardial ischaemia, hypertension, heart failure, cardiac

imaging (2013-2014-2015)

- Haute Autorité de Santé (France) : Pratiques professionnelles et Securité des soins (2013-2014-2015)

- Correvio : anti thrombotic agents (2015)

D - Research funding (departmental or institutional).- Société Française de Cardiologie : research funding (2013)

- Fondation Coeur et Recherche : general cardiology. Research funding (2013-2014)

Imazio Massimo Nothing to be declared (2013)

C - Receipt of royalties for intellectual property.- UptoDate, Wolters Kluwer Health : Medical Publisher (2014-2015)

D - Research funding (departmental or institutional).- SOBI : Anakinra and recurrent pericarditis (2014-2015)

- Acarpia srl Madeira, Portugal : Colchicine and pericarditis (2014-2015)

- FARGIM, Catania, Italy : Colchicine and pericarditis (2014-2015)

27/08/2015




2/33

Klingel Karin D - Research funding (departmental or institutional).- Novartis : Research on IL-1ß in myocarditis (2013-2014-2015)

Lionis Christos A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Amgen : Speaker fees (2013)

- GlaxoSmithKline : Speaker fees (2013)

- Pfizer Hellas : Speaker fees (2013)

- Spring to Life Ltd : Teaching fees (2015)

B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Leo Pharma : consultancy fees (2014)

- MSD : speaker fees (2014)

- UCB : speaker fees (2014)

- Vianex : speaker fees (2014)

- APR : speaker fees (2014)

- Pfizer International Operations : speaker fees (2014)

- GlaxoSmithKline : teaching fees (2014)

D - Research funding (departmental or institutional).- Pfizer : Community acquired pneumonia epidemiological research study. No product or therapeutic area. (2013)

Maisch Bernhard A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Springer Company, Managing Editor of HERZ/Cardiovascular Diseases : Medical Review Journal (2013)

- Springer Company : Honorarium as Editor of HERZ/Cardiovascular Diseases (2014)

- Biotest company : i.v. Immunoglobulins (2015)

Mayosi Bongani Mawethu Nothing to be declared (2015)

D - Research funding (departmental or institutional).- Pfizer, Servier, and AstraZeneca : Heart Failure (2013)

E - Research funding (personal).- Pfizer, Servier, and AstraZeneca : Heart Failure (2013)

27/08/2015




3/33

Mayosi Bongani Mawethu - Astra Zeneca : Heart Failure (2014)

- Novartis : Rheumatic heart disease (2014)

- Cadila Pharma : Tuberculous pericarditis (2014)

Pavie Alain Nothing to be declared (2013-2014-2015)

Ristic Arsen A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Richter Gedeon : Hypertension, Angina pectoris (2013)

- Teva Pharmaceutical Industries : Hypertension, Heart Failure (2013)

- Merck Serono : Bisoprolol and combination therapy (2013-2014)

- Abbott : Hypertension (2013-2014)

- Servier : Angina pectoris, Heart Failure (2013-2014-2015)

- Boehringer-Ingelheim : Novel oral anticoagulants (2013-2014-2015)

- Astra Zeneca : Ticagrelor (2013-2014-2015)

- Sanofi Aventis : Alirocumab clinical trial (2014-2015)

- Roche Pharma : Cardio-renal interactions in diabetic patients (2014-2015)

- Pfizer : Cardiovascular risk, Pulmonary hypertension (2014-2015)

- Genzyme : Fabry disease (2014-2015)

- Berlin Chemie AG : heart failure, arterial hypertension (2014-2015)

- Krka Pharma : Hypertension (2015)

- Hemofarm A.D. : Hypertension (2015)

D - Research funding (departmental or institutional).- Ministry of Science and Education of the Republic of Serbia : Heart failure, Myocardial and Pericardial Diseases (2013-2014-

2015)

E - Research funding (personal).- Ministry of Science and Education of the Republic of Serbia : Heart failure, Myocardial and Pericardial Diseases (2013-2014-

2015)

27/08/2015




4/33

Sabate Tenas Manel A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Medtronic : stent (2013)

- Abbott Vascular : Stent (2013-2014-2015)

Seferovic Petar B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Boehringer-Ingelheim : heart failure, hypertension (2013-2014-2015)

- Pfizer : heart failure, hypertension (2013-2014-2015)

- Berlin Chemie AG : heart failure, hypertension (2013-2014-2015)

- Richter Gedeon : hypertension (2013-2014-2015)

D - Research funding (departmental or institutional).- Ministry of Science and Education of the Republic of Serbia : heart failure, myocardial and pericardial disease (2013-2014-

2015)

Swedberg Karl A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Amgen : Heart Failure (2013-2014-2015)

- Novartis : Heart Failure (2013-2014-2015)

- Servier : Heart Failure (2013-2014-2015)

- Vifor Pharma : Heart Failure (2013-2014-2015)

B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Amgen : Heart Failure (2013)

- Servier : heart Failure (2013-2014-2015)

Tomkowski Witold Zbyszek A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Bayer, Boehringer, Daichi Sankyo : thrombosis (2013)

- Bayer : thrombosis (2014)

- Portola Pharmaceuticals : Thrombosis (2015)

- Aspen : Thrombosis (2015)

27/08/2015




5/33

Abaci Adnan A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Novartis : Hypertension (2013)

- Bristol Myers Squibb : Oral anticoagulation for atrial fibrillation (2013)

- Menarini : Hypertension (2013-2014)

- Astra Zeneca : Acute Coronary Syndrome (2013-2015)

- Bristol Myers Squibb : Anticoagulation (2014)

- Astra Zeneca : Antiplatelet (2014)

- Pfizer : Atrial fibrillation (2015)

Aboleineen Mohamed Wafaie

Nothing to be declared (2015)

A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Novartis : antihypertensive (2013-2014)

Achenbach Stephan A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Bayer : Anticoagulation (2013)

- Behring : Anticoagulation (2013)

- Astra Zeneca : Antiplatelet Therapy (2013)

- Abbott : Coronary Intervention (2013)

- Siemens Healthcare : CT (2013)

- Servier : Imaging (2013)

- Guerbet : Imaging (2013)

D - Research funding (departmental or institutional).- Abbott : Coronary Intervention (2013-2014)

- Siemens Healthcare : Imaging (2013-2015)

Agewall Stefan A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Böhringer Ingelheim : Anticoagulatn treatment (2013)

- Roche Diagnostics : Cardiac markers (2013)

27/08/2015

Guidelines on Pericardial Diseases 2015 (TF18) - Document Reviewers



6/33

Agewall Stefan - Orion : Heart failure (2013)

- Pfizer : Lipids (2013)

- Sanofi Aventis : Lipids (2013)

- Siemens Healthcare : Markers (2013)

- Astra Zeneca : Platelet inhibition (2013-2014-2015)

- Thermo Fischer Scientific : Cardiac markers (2014-2015)

Al-Attar Nawwar A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Johnson & Johnson : haemostasis (2013-2014-2015)

Andersson Bert A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Servier : Heart failure (2013-2014-2015)

B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Medtronic : Renal denervation (2014-2015)

- Recor Medical : Renal denervation (2014-2015)

Angel Ferrer Juan Nothing to be declared (2013-2014-2015)

Antov Slobodan Nothing to be declared (2013-2014-2015)

Arad Michael Nothing to be declared (2013-2014)

A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Genzyme : Fabrazyme (2015)

Archbold Andrew Nothing to be declared (2013-2014-2015)

Arutyunov Grigory P A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Takeda Pharmaceuticals : Loop Diuretics (2013-2014-2015)

- Berlin Chemie AG : Beta-blockers (2015)

- Servier : If blockers (2015)

E - Research funding (personal).- Takeda Pharmaceuticals : Loop Diuretics (2013-2014-2015)

27/08/2015




7/33

Asteggiano Riccardo A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Chiesi Pharma : Rosuvastatin (2013-2014)

- Edwards Lifesciences : Prosthetic valves (2015)

Bouma Berto Nothing to be declared (2013-2014-2015)

Bueno Hector A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- BMS/Pfizer : Apixaban (2013)

- Roche Pharma : Dalcetrapib (2013)

- Novartis : Relaxin (2013)

- Bayer Healthcare : Aspirin, rivaroxaban (2013-2014-2015)

- Sanofi Aventis : Clopidogrel (2013-2014-2015)

- Daiichi Sankyo : Prasugrel (2013-2014-2015)

- Eli Lilly : Prasugrel (2013-2014-2015)


- Novartis : Serelaxin (2014)

- Pfizer : Apixaban (2014-2015)

- Bristol Myers Squibb : Apixaban (2014-2015)

- Servier : ivabradine (2014-2015)

- Menarini : Ranolazine (2014-2015)

- Abbott : Absorb stent (2015)

- Novartis : Serelaxin, ACZ696 (2015)

- Ferrer Internacional : Trinomia (polypill) (2015)

D - Research funding (departmental or institutional).- Astra Zeneca : Funding of TAN-SNIP observational study. No drugs involved (2015)

27/08/2015




8/33

Bueno Hector E - Research funding (personal).- Astra Zeneca : Ticagrelor (2013-2014-2015)

Caforio Alida L P Nothing to be declared (2013-2014-2015)

Carerj Scipione Nothing to be declared (2013-2014-2015)

Ceconi Claudio Nothing to be declared (2013-2014-2015)

Codreanu Andrei Nothing to be declared (2013-2014-2015)

Damy Thibaud A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Alnylam : Amyloidosis (2013-2014)

- Free binding site : Amyloidosis (2013-2014)

- Pfizer : amyloidosis, heart failure, pulmonary hypertesnion (2013-2014)

- Astra Zeneca : Heart failure (2013-2014)

- Servier : Heart failure (2013-2014)

- Sorin Group : Heart failure (2013-2014)

- Vifor International : Heart failure and anemia (2013-2014)

- Novartis : Heart failure and heart transplantation (2013-2014)

- Resmed : Sleep apnea (2013-2014)

B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Pfizer : Amyloidosis (2013-2014)

- Novartis : Cardiac transplantation (2013-2014)

- Actelion : Pulmonary hypertension (2013-2014)

- Resmed : Sleep apnea (2013-2014)

- Pfizer : Amyloidosis and PAH (2015)

- Daiichi Sankyo : Anticoagulant (2015)

- Resmed : SDB (2015)

27/08/2015




9/33

Dimitriadis Kyriakos Nothing to be declared (2013-2014-2015)

Dimulescu Doina Ruxandra A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Bayer : atrial fibrillation (2013)

- Pfizer : atrial fibrillation (2013)

- Bristol Myers Squibb : atrial fibrillation (2013)

- Servier : Heart failure (2013)

- Berlin Chemie AG : hypertension (2013)

- Krka Pharma : hypertension (2013)

- Zentiva : ischemic heart disease (2013)

- Novartis : hypertension (2013-2014-2015)

- Astra Zeneca : ischemic heart disease (2013-2014-2015)

- Servier : Hypertension, heart failure (2014)

- Pfizer : Anticoagulant therapy (2014-2015)

- Boehringer Ingelheim : anticoagulant therapy (2014-2015)

- Brigham and Women s Hospital : Antiplatelet therapy (2014-2015)

- Sanofi Aventis : Dyslipidemia (2014-2015)

- Romanian Society of hypertension : Hypertension (2014-2015)

- Servier : antihypertensive therapy (2015)

- Krka Pharma : antihypertensive therapy (2015)

- Brigham and Women Hospital : antiplatelet therapy (2015)

- Bayer : antithrombotic therapy (2015)

- Boehringer-Ingelheim : antithrombotic therapy (2015)

- Pfizer : antithrombotic therapy (2015)

27/08/2015




10/33

Dimulescu Doina Ruxandra - Astra Zeneca : atherosclerosis (2015)

- Sanofi Aventis : atherosclerosis (2015)

- Labormed : atherosclerosis (2015)

B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Astra Zeneca : ischemic heart disease (2013)

- Sanofi Aventis : ischemic heart disease (2013)

- Astra Zeneca : ANTIPLATELET THERAPY (2014)

- Sanofi Aventis : Acute coronary syndrome (2014-2015)

- Astra Zeneca : antithrombotic therapy (2015)

D - Research funding (departmental or institutional).- ANCS BIOMARCAD Trial : atherosclerosis (2015)

Dingli Philip Nothing to be declared (2013-2014-2015)

Dubrava Juraj A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Servier : ivabradine (2013-2014-2015)

- Boehringer-Ingelheim : dabigatran (2014-2015)

- Bayer AG : rivaroxaban (2014-2015)

El Hattaoui Mustapha Nothing to be declared (2015)

A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Pfizer : advisory board fees on APIXABAN (2013-2014)

Evangelista Masip Artur Nothing to be declared (2013-2014-2015)

Flachskampf Frank Arnold Nothing to be declared (2013-2014-2015)

Gatzov Plamen Marinov Nothing to be declared (2013-2014-2015)

Giannakoulas George A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Novartis : Acute Heart Failure (2013-2014)

- Astra Zeneca : Cardiovascular risk (2013-2014)

27/08/2015




11/33

Giannakoulas George - Menarini : Chronic coronary artery disease (2013-2014)

- Bayer : Pulmonary Hypertension (2013-2014)

- Actelion : Pulmonary Hypertension (2013-2014)

- Pfizer : Chronic Heart Failure, Atrial Fibrillation (2014)

- Servier : Chronic coronary artery disease (2014-2015)

- MSD : Hyperlipidemia (2014-2015)

- Pfizer : Atrial Fibrillation (2015)

- Astra Zeneca : Coronary artery disease (2015)

- Bayer : Pulmonary Hypertension - Atrial Fibrillation (2015)

Gielen Stephan A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Astra Zeneca : Lectures 2013 (2013)

- Bayer Healthcare : Lectures 2013 (2013)

- Novartis : Lectures 2013-14, Travel grant AHA (2013)

- Boston Scientific : Lecture (2014)

- Servier : Lectures 2013 (2014)

- Novartis : Lectures 2014 (2014)

- Astra Zeneca : Lecture/Chairperson 2014, Advisory Board (2014-2015)

- Sanofi Aventis : Lecture, Travel Grant (2015)

- Elixier : Travel Grant (2015)

Habib Gilbert A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Actelion : pulmonary hypertension (2013-2014)

B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Pfizer : pulmonary hypertension (2013-2014-2015)

- Abbott : Mitraclip (2015)

27/08/2015




12/33

Habib Gilbert - Actelion : Pulmonary Hypertension (2015)

D - Research funding (departmental or institutional).- Genzyme : Fabry's disease (2015)

Heracleous Hera Nothing to be declared (2013-2014-2015)

Hoffman Piotr A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Abbott, Servier, Bayer, Actelion, General Electric, Polpharma, : cardiological drugs, echo machines (2013)

- Abbott, Servier, Polpharma, Merck, MSD, Novartis, Amgen, Berlin-Chemie, General Electric, Actelion, Bayer, : cardiological drugs, echo machines (2014-2015)

Isayev Elnur Nothing to be declared (2013-2014-2015)

Kavoliuniene Ausra A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Astra Zeneca : beta blockers use in CVD (2013)

- Krka Pharma : ARBs - Speaker's fee (2013-2014-2015)

- Berlin Chemie AG : BB - Speaker's fee (2013-2014-2015)

- Servier : RCTs, Speaker's Fee (2013-2014-2015)

- Bayer : Speaker's fee (2014)

- Remedica : NOACs - Speaker's fee (2014-2015)

- Bayer : Speaker's fee, Investigator fee (2015)

D - Research funding (departmental or institutional).- Novartis : Serelaxin (2015)

- Cardiorentis : Ularitide (2015)

Kiss Robert Gabor A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Pfizer : apixaban (2013-2014-2015)

- Boehringer-Ingelheim : dabigatran (2013-2014-2015)

- Bayer Healthcare : rivaroxaban (2013-2014-2015)

B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- TIMI group : steering committee member (2013-2014-2015)

27/08/2015




13/33

Kolh Philippe H A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- B.Braun : Surgical instruments (2013-2014)

- Astra Zeneca : Antiplatelet agents (2013-2014-2015)

D - Research funding (departmental or institutional).- St Jude Medical : Cardiac valves (2013)

- Boston Scientific : Coronary stents (2013)

- Siemens Healthcare : Medical imaging (2013)

- Johnson & Johnson : Thoracoscopic devices (2013)

- Edwards Lifesciences : Cardiac valves (2013-2014-2015)

- Medtronic : Cardiac valves (2013-2014-2015)

Lambrinou Ekaterini Nothing to be declared (2013)

A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Novartis : Consultancy, AHF Academy. (2014)

- Novartis : Consultancy, AHF Academy. Honorarium, Novartis-supported Satellite Symposium at EuroHeartCare 2015. (2015)

Lancellotti Patrizio A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Servier : Heart Failure (2013)

- Abbott : MitraClip (2013)

- Menarini : nebivolol (2014)

- St Jude Medical : Heart Failure (2015)

B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Astrazeneca : Dyslipidemia (2013)

- Boston Scientific : CRT (2014)

- Servier : procoralan (2014)

- Daiichi Sankyo : Teaching course on imaging (2015)

27/08/2015




14/33

Lancellotti Patrizio D - Research funding (departmental or institutional).- Actelion : Pulmonary Hypertension (2013)

Lazaros George Nothing to be declared (2013-2014-2015)

Lehtonen Jukka A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Astra-Zeneca : Ischemic herat disease (2013-2014-2015)

Linhart Ales A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- GlaxoSmithKline : Atherosclerosis (2013)

- Servier : Arterial hypertension (2013-2014-2015)

- Boehringer-Ingelheim : Arterial hypertension, atrial fibrillation (2013-2014-2015)

- Merck Sharp & Dohme : Dyslipidemia (2013-2014-2015)

- Bayer Schering Pharma : Dyslipidemia, pulmonary hypertension, atrial fibrillation (2013-2014-2015)

- Shire HGT : Fabry disease (2013-2014-2015)

- Genzyme : Fabry disease (2013-2014-2015)

- Actelion : Pulmonary hypertension (2013-2014-2015)

D - Research funding (departmental or institutional).- Shire HGT : Fabry disease (2014-2015)

Mascherbauer Julia A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- AOP Orphan Pharmaceuticals : pulmonary hypertension, heart failure (2013)

- Novartis : heart failure (2013-2014)

E - Research funding (personal).- Novartis : HFpEF (2015)

Meurin Philippe A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Servier : ivabradine (2013-2014-2015)

Mirrakhimov Erkin Nothing to be declared (2013-2014-2015)

Moller Jacob Eifer A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Abiomed : Impella (2013-2014)

- Novartis : Speaker fee (2013-2014)

27/08/2015




15/33

Moller Jacob Eifer - Astra Zeneca : Speaker Fee, acute heart failure (2013-2014)

- Orion : Levosimendan (2015)

- Abiomed : Percoutaneous mechanical support (2015)

Mueller Hajo B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Pfizer CH : Support of lunch (sandwiches) for CME meeting (echocardiography) in 2013 (2013)

- Pfizer CH : Support of lunch (sandwiches) for CME meeting (echocardiography) in 2014 (2014)

- Bayer AG : Support of lunch (sandwiches) for CME meeting (echocardiography) in 2014 (2015)

Nesukay Elena A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Servier : cardiology (2013-2014-2015)

Nieman Koen A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Toshiba medical imaging : Computed tomography (2013)

- Siemens Healthcare : Computed tomography (2013-2014-2015)

D - Research funding (departmental or institutional).- Bayer Healthcare : Contrast media (2013-2014-2015)

- GE Healthcare : Contrast media (2014-2015)

- Siemens Medical Solutions : Imaging (2014-2015)

Novo Salvatore Nothing to be declared (2015)

A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Phidea Group as Coordinator of the CAD Study : Ranolazine (2013)

- MSD : Statins (2014)

B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Sanofi Aventis : Elirocumab (2013)

- Bristol Myers Squibb : Apixaban (2014)

Pavlovic Milan Nothing to be declared (2013-2014-2015)

Piepoli Massimo Francesco Nothing to be declared (2013-2014-2015)

27/08/2015




16/33

Poder Pentti A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Cardiorentis : Acute Heart Failure (2013-2014-2015)

B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Cardiorentis : Acute Heart Failure (2014-2015)

Price Susanna Nothing to be declared (2014-2015)

A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Medtronic : educational contract (2013)

B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Abbott : MItraclip (2013)

Rafnsson Arnar Nothing to be declared (2013)

A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Amgen : Fourier study (2014-2015)

Rocha Lopes Luis Nothing to be declared (2013)

A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Genzyme : Fabry (2014-2015)

- Health in Code SL : Genetics (2015)

- Novartis : Oncology (cardio-oncology) (2015)

Roos-Hesselink Jolien W Nothing to be declared (2013-2014-2015)

Roubille Francois A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Astra Zeneca : Coronary artery disease (2013-2014-2015)

- Amgen Inc : Dyslipidémia (2013-2014-2015)

- Merck Sharp & Dohme : dyslipidémie (2013-2014-2015)

- Novartis : Heart Failure (2013-2014-2015)

- Servier : Heart failure (2013-2014-2015)

- Medtronic : Interventional Cardiology (2013-2014-2015)

D - Research funding (departmental or institutional).- Astra Zeneca : Sleep apnea (2013-2014-2015)

27/08/2015




17/33

Roubille Francois - Daiichi Sankyo : Antiplatelet (2015)

E - Research funding (personal).- Servier : Heart failure (2013)

Ruschitzka Frank A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Biotronik : Devices (2013)

- Servier : Drugs (2013-2014-2015)

B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Bayer : Postgraduate Heart Failure Course (Grant to Zurich Heart House) (2013-2014-2015)

- Novartis : Postgraduate Heart Failure Course (Grant to Zurich Heart House) (2013-2014-2015)

- St Jude Medical : Postgraduate Heart Failure Course (Grant to Zurich Heart House) (2013-2014-2015)

D - Research funding (departmental or institutional).- Mars : Flavanol-like cocoa products (2013-2014-2015)

Sagrista Sauleda Jaime Nothing to be declared (2013-2014-2015)

Samstad Stein Olav Nothing to be declared (2013-2014-2015)

Schieffer Bernhard A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Abiomed; Bayer, Astra Zeneca, : anticoagulants, mechanical heart support systems (2013-2014)

- Abiomed; Bayer, Zoll : anticoagulants, life vest (2014)

- Abiomed, Zoll, marquette, pfizer, bayer : Cardiogenic shock (2015)

D - Research funding (departmental or institutional).- Deutsche Forschungsgemeinschaft : none (2013)

- BMBF - German Ministry of Research and Education : none (2013)

- Deutsche Herzstiftung : none (2013)

Separovic Hanzevacki Jadranka

A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Servier : Ivabradin (2013)

- Merck Sharp & Dohme : Zofenopril (2013)

- Servier : Hypertension and CHF (norprexanil and ivabradin) (2014)

27/08/2015




18/33

Separovic Hanzevacki Jadranka

- Berlin Chemie AG : ACE inhibitor (2014-2015)

- Genzyme : Fabry disease (2015)

- Servier : Hypertension and CHF (norprexanil CCA and diuretic combinaton) (2015)

Shuka Naltin Nothing to be declared (2013-2014-2015)

Shumavets Vadim Nothing to be declared (2013-2014-2015)

Sisakian Hamayak A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Servier : Investigator, Speaker fee (2013)

- Servier : Hypertension (2014)

- Servier : Indapamide/Amlodipin (2015)

- Bayer : Rivaroxaban (2015)

B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Servier : Investigator (2013)

- Servier : Indapamide/Amlodipin (2015)

D - Research funding (departmental or institutional).- Yerevan State Medical University : No (2015)

Sousa Uva Miguel Nothing to be declared (2013-2014-2015)

Stradins Peteris Nothing to be declared (2013-2014-2015)

Van Camp Guy Nothing to be declared (2013-2014-2015)

Vataman Eleonora A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Bayer Healthcare : Consultancy (2013)

- Sanofi Aventis : Speaker fee (2013)

- GEdeon Rihter : Speaker fee (2013)

- Egis Pharma : consultancy (2014)

- Servier : speaker (2014)

27/08/2015




19/33

Vataman Eleonora - Sanofi Aventis : speaker (2014)

- Berlin Chemie AG : speaker (2014)

- Promed : speaker (2014-2015)

- Krka Pharma : Consultancy (2015)

- Gedeon Rrigter : Consultancy (2015)

- Egis Pharma : scientific collaboration (2015)

Voigt Jens-Uwe A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- GE Healthcare : Ultrasound (2013-2014-2015)

D - Research funding (departmental or institutional).- Hitachi-Aloka : Ultrasound (2013)

- Philips : Ultrasound (2013-2014)

- GE Healthcare : Ultrasound (2013-2014)

- Toshiba medical imaging : Ultrasound (2013-2014)

Zamorano Gomez Jose Luis

A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Daiichii : Atrial Fib (2013)

- Merck Sharp & Dohme : Lipid Lowering (2013)

- Philips : 3D echo (2014)

- Toshiba medical imaging : fusion imaging 3D echo CT (2014)

- Astra Zeneca : Speaker fee for 1 talk in 2014 (2014)

- MSD : CV risk factors (2014-2015)

- Abbott : Lecturing (2015)

- Astra Zeneca : Lecturing (2015)

- Pfizer : Lecturing (2015)

- Sorin Group : Respicardia echo protocol (2015)

27/08/2015




20/33


B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- European Research FP7 : CV Imaging (2013)

- Servier : Imaging in ISchemic patients (2013)

- Siemens Healthcare : 3d echo software and free style echo (2014-2015)

- Toshiba medical imaging : Fusion Imaging (2015)

C - Receipt of royalties for intellectual property.- Springer : ESC Textbook of CV Imaging (2013)

D - Research funding (departmental or institutional).- Amgen : Clinical trial (2014-2015)

- Novartis : Clinical trial (2014-2015)

- Ikaria : Clinical trial (2014-2015)

27/08/2015




21/33

Aboyans Victor Nothing to be declared (2013)

A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Astra Zeneca : Antithrombotics (2014)

- Sanofi Aventis : Hyperlipidemia (2014)

- Boehringer-Ingelheim : Oral anticoagulation (2014)

- Pfizer/BMS alliance : Oral anticoagulation (2014)

- Novartis : Hypertension (2014-2015)

- Bayer Healthcare : Oral anticoagulation (2014-2015)

- Merck Sharp & Dohme : Antithrombotics (2015)

Achenbach Stephan A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Bayer : Anticoagulation (2013)

- Behring : Anticoagulation (2013)

- Astra Zeneca : Antiplatelet Therapy (2013)

- Abbott : Coronary Intervention (2013)

- Siemens Healthcare : CT (2013)

- Servier : Imaging (2013)

- Guerbet : Imaging (2013)

D - Research funding (departmental or institutional).- Abbott : Coronary Intervention (2013-2014)

- Siemens Healthcare : Imaging (2013-2015)

Agewall Stefan A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Böhringer Ingelheim : Anticoagulatn treatment (2013)

- Roche Diagnostics : Cardiac markers (2013)

- Orion : Heart failure (2013)

27/08/2015

Committee for Practice Guidelines 2014-2016 - MEMBERS



22/33

Agewall Stefan - Pfizer : Lipids (2013)

- Sanofi Aventis : Lipids (2013)

- Siemens Healthcare : Markers (2013)

- Astra Zeneca : Platelet inhibition (2013-2014-2015)

- Thermo Fischer Scientific : Cardiac markers (2014-2015)

Badimon Lina A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Astra Zeneca : cardiovascular (2013)

- Sanofi Aventis : cardiovascular (2013)

- MSD-España : Lipids (2014)

- Sanofi Aventis : lipids (2014-2015)

- Burson Masteller : nutrition (2014-2015)

- Astra Zeneca : thrombosis (2014-2015)

D - Research funding (departmental or institutional).- Astrazeneca : thrombosis (2014-2015)

Baron Esquivias Gonzalo A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Bayer : Anticoagulation (2013-2014-2015)

- Boehringer-Ingelheim : Anticoagulation (2013-2014-2015)

- Daiichi Sankyo : Anticoagulation (2013-2014-2015)

- Pfizer : Anticoagulation (2013-2014-2015)

- Menarini : Ischemic disease (2015)

- Laboratorios Rovi : Ivabradine (2015)

D - Research funding (departmental or institutional).- Biotronik : Vasovagal syncope & Pacing (2013)

- Bayer : Anticoagulation (2015)

27/08/2015




23/33

Baumgartner Helmut A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Actelion : Bosentan and Macicentan for PAH treatment in congenital heart disease (2013-2014-2015)

- St. Jude Medical : Occluders for shunt closure (ASD, PFO, PDA, VSD) (2013-2014-2015)

- Abbott : transcather mitral valve repair (Mitraclip) (2013-2014-2015)

- Edwards Lifesciences : transcatheter valve implantation (2013-2014-2015)

- Direct Flow Medical : transcatheter valve implantation (2013-2014-2015)

B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Actelion : Bosentan for PAH treatment in congenital heart disease (2013-2014-2015)

- St. Jude Medical : Occluders for shunt closure (ASD, PFO, PDA, VSD) (2013-2014-2015)

- Abbott : transcather mitral valve repair (Mitraclip) (2013-2014-2015)

- Edwards Lifesciences : transcatheter valve implantation (2013-2014-2015)

- Direct Flow Medical : transcatheter valve implantation (2013-2014-2015)

Bax Jeroen Nothing to be declared (2014-2015)

D - Research funding (departmental or institutional).- Servier : Farma (2013)

- Edwards Lifesciences : Heart Valves (2013)

- GE Healthcare : Imaging (2013)

- Lantheus Inc : Imaging (2013)

- Boston Scientific : Pacing (2013)

- Medtronic : Pacing (2013)

- St Jude Medical : Pacing (2013)

- Biotronik : Pacing (2013)

Bueno Hector A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- BMS/Pfizer : Apixaban (2013)

27/08/2015




24/33

Bueno Hector - Roche Pharma : Dalcetrapib (2013)

- Novartis : Relaxin (2013)

- Bayer Healthcare : Aspirin, rivaroxaban (2013-2014-2015)

- Sanofi Aventis : Clopidogrel (2013-2014-2015)

- Daiichi Sankyo : Prasugrel (2013-2014-2015)

- Eli Lilly : Prasugrel (2013-2014-2015)


- Novartis : Serelaxin (2014)

- Pfizer : Apixaban (2014-2015)

- Bristol Myers Squibb : Apixaban (2014-2015)

- Servier : ivabradine (2014-2015)

- Menarini : Ranolazine (2014-2015)

- Abbott : Absorb stent (2015)

- Novartis : Serelaxin, ACZ696 (2015)

- Ferrer Internacional : Trinomia (polypill) (2015)

D - Research funding (departmental or institutional).- Astra Zeneca : Funding of TAN-SNIP observational study. No drugs involved (2015)

E - Research funding (personal).- Astra Zeneca : Ticagrelor (2013-2014-2015)

Carerj Scipione Nothing to be declared (2013-2014-2015)

Erol Cetin A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Servier : Hypertension (2013-2014-2015)

B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Menarini : Hypertension (2013-2014-2015)

27/08/2015




25/33

Fitzsimons Donna Nothing to be declared (2013-2015)

A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Amgen : FH Tratment options (2014)

Gaemperli Oliver Nothing to be declared (2013)

A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Biosensors : Stents (2014)

- Biosensors : Axxess Bifurcation Stent (2015)

- Abbott Vascular : MitraClip (2015)

- Biosensors : Travel Grant to AsiaPCR 2015 (2015)

Kirchhof Paulus A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Otsuka Pharmaceuticals Development and Commercialization (consultancy) : cardiovascular (2013)

- Boehringer-Ingelheim : cardiovascular (2013-2014-2015)

- Daiichi Sankyo : cardiovascular (2013-2014-2015)

- Medtronic : cardiovascular (2013-2014-2015)

- Pfizer : cardiovascular (2013-2014-2015)

- St Jude Medical : cardiovascular (2013-2014-2015)

- Sanofi Aventis : cardiovascular (2013-2014-2015)

- Meda pharma : cardiovascular (2013-2014-2015)

- Bristol Myers Squibb : cardiovascular (2013-2014-2015)

- Merck Sharp & Dohme : cardiovascular (2013-2014-2015)

- Medscape : cardiovascular (2014-2015)

- Bayer Healthcare : cardiovascular (2015)

- Correvio : cardiovascular (2015)

- Remedica : cardiovascular (2015)

27/08/2015




26/33

Kirchhof Paulus B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Boehringer-Ingelheim : cardiovascular (2013)

- Bayer Healthcare : cardiovascular (2013)

- Gilead : cardiovascular (2013)

- BMS / Pfizer alliance : cardiovascular (2013)

D - Research funding (departmental or institutional).- St Jude Medical : cardiovascular (2013-2014-2015)

- Sanofi Aventis : cardiovascular (2013-2014-2015)

- Meda pharma : cardiovascular (2013-2014-2015)

- Daiichi Sankyo : cardiovascular (2014-2015)

- British Heart Foundation : cardiovascular (2014-2015)

- BMS / Pfizer alliance : cardiovascular (2014-2015)

- Leducq Foundation : cardiovascular (2014-2015)

- European Union FP7 : cardiovascular (2014-2015)

- European Union horizon2020 : cardiovascular (2014-2015)

- German Centre for Heart Research (DZHK, funded by German Ministry of Education and Research) : cardiovascular (2014-2015)

Kolh Philippe H A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- B.Braun : Surgical instruments (2013-2014)

- Astra Zeneca : Antiplatelet agents (2013-2014-2015)

D - Research funding (departmental or institutional).- St Jude Medical : Cardiac valves (2013)

- Boston Scientific : Coronary stents (2013)

- Siemens Healthcare : Medical imaging (2013)

- Johnson & Johnson : Thoracoscopic devices (2013)

27/08/2015




27/33

Kolh Philippe H - Edwards Lifesciences : Cardiac valves (2013-2014-2015)

- Medtronic : Cardiac valves (2013-2014-2015)

Lancellotti Patrizio A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Servier : Heart Failure (2013)

- Abbott : MitraClip (2013)

- Menarini : nebivolol (2014)

- St Jude Medical : Heart Failure (2015)

B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Astrazeneca : Dyslipidemia (2013)

- Boston Scientific : CRT (2014)

- Servier : procoralan (2014)

- Daiichi Sankyo : Teaching course on imaging (2015)

D - Research funding (departmental or institutional).- Actelion : Pulmonary Hypertension (2013)

Lip Gregory Y H A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Astellas : atrial fibrillation, thrombosis (2013)

- Biotronik : atrial fibrillation (2013-2014-2015)

- Boehringer-Ingelheim : atrial fibrillation, thrombosis (2013-2014-2015)

- Daiichi Sankyo : atrial fibrillation, thrombosis (2013-2014-2015)

- Pfizer : atrial fibrillation, thrombosis (2013-2014-2015)

- Bayer Healthcare : atrial fibrillation, thrombosis (2013-2014-2015)

- Bristol Myers Squibb : atrial fibrillation, thrombosis (2013-2014-2015)

- Medtronic : atrial fibrillation (2014-2015)

- Roche Diagnostics : anticoagulation (2015)

27/08/2015




28/33

Lip Gregory Y H D - Research funding (departmental or institutional).- Bayer : atrial fibrillation, thrombosis (2013)

- Daiichi Sankyo : atrial fibrillation, thrombosis (2014-2015)

Nihoyannopoulos Petros Nothing to be declared (2014-2015)

A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- GSK : Consultant for Imaging studies (2013)

Piepoli Massimo Francesco Nothing to be declared (2013-2014-2015)

Ponikowski Piotr A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Bayer : anticoagulant (2013)

- Bristol Myers Squibb : anticoagulant (2013)

- ROSCHE : diabetes (2013)

- Boehringer-Ingelheim : anticoagulant (2013-2014)

- Respicardia : anticoagulant (2013-2014)

- Johnson & Johnson : heart failure (2013-2014)

- Pfizer : heart failure, anticoagulant (2013-2014)

- Abbott Vascular : devices (2013-2014-2015)

- Novartis : heart failure (2013-2014-2015)

- Cardiorentis : heart failure (2013-2014-2015)

- Bayer Healthcare : heart failure (2013-2014-2015)

- Vifor Pharma ltd : heart failure (2013-2014-2015)

- CIBIEM : heart failure (2013-2014-2015)

- Servier : heart failure, coronary artery disease (2013-2014-2015)

- Amgen : heart failure, lipids (2013-2014-2015)

- MSD : lipids (2014)

27/08/2015




29/33

Ponikowski Piotr - Astra Zeneca : acute coronary syndrome (2014-2015)

- Boehringer-Ingelheim : anticoagulant, diabetes (2015)

- Respicardia : devices (2015)

- BioControl : devices (2015)

- DC Device : devices (2015)

- Celladon : heart failure (2015)

B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Vifor Pharma ltd : heart failure (2014)

- MSD : lipids (2014)

- Astra Zeneca : acute coronary syndrome (2014-2015)

- Respicardia : anticoagulant (2014-2015)

- Novartis : heart failure (2014-2015)

- Cardiorentis : heart failure (2014-2015)

- Bayer Healthcare : heart failure (2014-2015)

- CIBIEM : heart failure (2014-2015)

- Servier : heart failure, coronary artery disease (2014-2015)

- Amgen : heart failure, lipids (2014-2015)

- BioControl : devices (2015)

- DC Device : devices (2015)

- Celladon : heart failure (2015)

D - Research funding (departmental or institutional).- Vifor Pharma ltd : heart failure (2013)

- Singulex : biomarkers (2015)

27/08/2015




30/33

Roffi Marco A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Daiichi Sankyo : antiplatelet therapy (2013)

- Lilly : antiplatelet therapy (2013)

- Astra Zeneca : antipletelet therapy (2013)

- Johnson & Johnson : coronary catheters (2014)

D - Research funding (departmental or institutional).- Biosensors : devices (2013-2014-2015)

- Boston Scientific : devices (2013-2014-2015)

- Medtronic : devices (2013-2014-2015)

- Biotronik : devices (2013-2014-2015)

- Abbott Vascular : devices (2013-2014-2015)

Torbicki Adam A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Bristol Myers Squibb : Pulmonary arterial hypertension (2013-2014-2015)

- GlaxoSmithKline : pulmonary arterial hypertension - ambrisentan (2013-2014-2015)

- Lilly : pulmonary arterial hypertension - ambrisentan (2013-2014-2015)

- Actelion : pulmonary arterial hypertension - macitentan, selexipag (2013-2014-2015)

- Bayer Healthcare : pulmonary arterial hypertention - iloprost, riociguat, VTE - xarelto (2013-2014-2015)

- AOP Orphan Pharmaceuticals : pulmonary arterial hypertension (2015)

B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Bayer Healthcare : Pulmonary hypertension (2013-2014-2015)

Vaz Carneiro Antonio Nothing to be declared (2015)

B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- AbbVie : Oncology (2013-2014)

Windecker Stephan A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Astra Zeneca : Antiplatelet drug (2013)

- Eli Lilly : Antiplatelet drug (2013)

27/08/2015




31/33

Windecker Stephan - Abbott : Stent (2013)

- Medtronic : Stent (2013)

- Biotronik : Stent (2013)

- Astra Zeneca : Antiplatelet therapy (2014-2015)

- Eli Lilly : Antiplatelet therapy (2014-2015)

- Bayer Healthcare : Antithrombotic drug (2014-2015)

- Abbott : Stent and Heartvalvetherapy (2014-2015)

- Biosensors : Stents (2014-2015)

- Boston Scientific : Stents (2014-2015)

- Medtronic : TAVI, Stent (2015)

- Edwards Lifesciences : Transcatheter heart valves (2015)

D - Research funding (departmental or institutional).- St Jude Medical : OCT (2013-2014-2015)

- Biotronik : Stent (2013-2014-2015)

- Medtronic : Stent and Heartvalves (2014)

- Medicines Company : Antithrombotic therapy (2014-2015)

- Johnson & Johnson : Catheters (2014-2015)

- Edwards Lifesciences : Heartvalves (2014-2015)

- Abbott : Stent (2014-2015)

- Boston Scientific : Stent and Heartvalves (2014-2015)


A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Daiichii : Atrial Fib (2013)

- Merck Sharp & Dohme : Lipid Lowering (2013)

27/08/2015




32/33


- Philips : 3D echo (2014)

- Toshiba medical imaging : fusion imaging 3D echo CT (2014)

- Astra Zeneca : Speaker fee for 1 talk in 2014 (2014)

- MSD : CV risk factors (2014-2015)

- Abbott : Lecturing (2015)

- Astra Zeneca : Lecturing (2015)

- Pfizer : Lecturing (2015)

- Sorin Group : Respicardia echo protocol (2015)

B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- European Research FP7 : CV Imaging (2013)

- Servier : Imaging in ISchemic patients (2013)

- Siemens Healthcare : 3d echo software and free style echo (2014-2015)

- Toshiba medical imaging : Fusion Imaging (2015)

C - Receipt of royalties for intellectual property.- Springer : ESC Textbook of CV Imaging (2013)

D - Research funding (departmental or institutional).- Amgen : Clinical trial (2014-2015)

- Novartis : Clinical trial (2014-2015)

- Ikaria : Clinical trial (2014-2015)

27/08/2015




33/33

Documents

Guidelines on Pericardial Diseases 2015 (TF18) - Task Force · PDF file- Cadila Pharma : Tuberculous pericarditis ... - Thermo Fischer Scientific : Cardiac markers ... - Eli Lilly